Form 4: Bionano Genomics Executive Receives Stock Options and Restricted Stock Units

Jonathan V. Dixon, General Counsel of Bionano Genomics, reports the acquisition of stock options and restricted stock units.

Summary

• On June 3, 2024, Jonathan V. Dixon, General Counsel of Bionano Genomics, acquired 68,000 stock options with an exercise price of $0.93.
• These options vest monthly over 48 months, starting on June 3, 2024, and will be fully vested by June 2, 2028.
• Dixon also received 14,500 restricted stock units (RSUs) that vest 1/4th annually, beginning on the one-year anniversary of the grant date.
• Following these transactions, Dixon directly owns 18,025 shares of Bionano Genomics common stock and 68,000 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of continued service and contribution from the executive.

Industry Context

Equity grants are a common practice in the biotechnology industry to incentivize and retain key personnel. The size and terms of the grants are generally aligned with industry standards for similar roles and company size.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Pacific Biosciences and Illumina also use stock options and RSUs to incentivize their executives.
• The vesting schedules (monthly for options, annual for RSUs) are typical for these types of grants.

Stakeholder Impact

• Shareholders: The equity grants align executive interests with shareholder value creation.
• Employees: The grants may have a positive impact on employee morale by demonstrating the company's commitment to its leadership.

Key Dates

Keywords

Bionano Genomics, BNGO, Jonathan V. Dixon, Stock Options, Restricted Stock Units, RSUs, Form 4, General Counsel, Equity Incentive Plan, Beneficial Ownership